Literature DB >> 19933804

Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.

Denis Frasca1, Sandrine Marchand, Franck Petitpas, Claire Dahyot-Fizelier, William Couet, Olivier Mimoz.   

Abstract

Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19933804      PMCID： PMC2812167          DOI： 10.1128/AAC.00836-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 2.  Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review.

Authors:  Caroline Fonzo-Christe; Caroline Vukasovic; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry
Journal:  Palliat Med       Date:  2005-04       Impact factor: 4.762

3.  Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.

Authors:  Goutam C Mistry; Anup K Majumdar; Suzanne Swan; Domenic Sica; Alison Fisher; Yang Xu; Michael Hesney; Liwen Xi; John A Wagner; Paul J Deutsch
Journal:  J Clin Pharmacol       Date:  2006-10       Impact factor: 3.126

4.  Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Marie-Claude Saux; Jean-Baptiste Gordien; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2006-10-13       Impact factor: 17.440

5.  Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis.

Authors:  Olaf Burkhardt; Martin Brunner; Stephan Schmidt; Maria Grant; Yufei Tang; Hartmut Derendorf
Journal:  J Antimicrob Chemother       Date:  2006-07-12       Impact factor: 5.790

6.  Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.

Authors:  Mathias W R Pletz; Mareike Rau; Juergen Bulitta; Andres De Roux; Olaf Burkhardt; Guido Kruse; Michael Kurowski; Carl E Nord; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.

Authors:  A Barbot; N Venisse; F Rayeh; S Bouquet; B Debaene; O Mimoz
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

8.  Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.

Authors:  D G Musson; A Majumdar; S Holland; K Birk; L Xi; G Mistry; D Sciberras; J Muckow; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 9.  Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.

Authors:  David E Nix; Anup K Majumdar; Mark J DiNubile
Journal:  J Antimicrob Chemother       Date:  2004-06       Impact factor: 5.790

10.  Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Authors:  Joseph S Solomkin; Albert E Yellin; Ori D Rotstein; Nicolas V Christou; E Patchen Dellinger; Jose M Tellado; Osvaldo Malafaia; Alvaro Fernandez; Kyuran A Choe; Alexandra Carides; Vilas Satishchandran; Hedy Teppler
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969
View more
  8 in total

1.  Bacterial Proliferation May Be the Key Component of Sepsis Mortality.

Authors:  Christian de Tymowski; Mario D T Correia; Renato C Monteiro; Philippe Montravers; Sanae Ben Mkaddem
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

2.  In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Authors:  Janet A Hindler; Annie Wong-Beringer; Carmen L Charlton; Shelley A Miller; Theodoros Kelesidis; Marissa Carvalho; George Sakoulas; Poochit Nonejuie; Joseph Pogliano; Victor Nizet; Romney Humphries
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

3.  Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.

Authors:  Andrea Endimiani; Federico Perez; Saralee Bajaksouzian; Anne R Windau; Caryn E Good; Yuvraj Choudhary; Andrea M Hujer; Christopher R Bethel; Robert A Bonomo; Michael R Jacobs
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

4.  A bio-analytically validated HPLC-UV method for simultaneous determination of doripenem and ertapenem in pharmaceutical dosage forms and human plasma: a dual carbapenem regimen for treatment of drug-resistant strain of Klebsiella pneumoniae.

Authors:  Marwa F B Ali; Mostafa A Marzouq; Samiha A Hussein; Baher I Salman
Journal:  RSC Adv       Date:  2021-01-14       Impact factor: 4.036

Review 5.  Hypodermoclysis: a literature review to assist in clinical practice.

Authors:  Vanessa Galuppo Bruno
Journal:  Einstein (Sao Paulo)       Date:  2015-03-24

6.  Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.

Authors:  Jeffrey A Klein; Loralie J Langman
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-30

7.  Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection.

Authors:  Sylvain Goutelle; Anne Conrad; Cécile Pouderoux; Evelyne Braun; Frédéric Laurent; Marie-Claude Gagnieu; Sabine Cohen; Jérôme Guitton; Florent Valour; Tristan Ferry
Journal:  Front Med (Lausanne)       Date:  2021-03-31

8.  Tumescent Injections in Subcutaneous Pig Tissue Disperse Fluids Volumetrically and Maintain Elevated Local Concentrations of Additives for Several Hours, Suggesting a Treatment for Drug Resistant Wounds.

Authors:  John P Koulakis; Joshua Rouch; Nhan Huynh; Holden H Wu; James C Y Dunn; Seth Putterman
Journal:  Pharm Res       Date:  2020-02-10       Impact factor: 4.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.